Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311144477> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4311144477 endingPage "100281" @default.
- W4311144477 startingPage "100281" @default.
- W4311144477 abstract "ENPP1 is a type II transmembrane protein with nucleotide pyrophosphatase, and phosphodiesterase enzymatic activities and its expression is associated with poor prognosis in cancer. ENPP1 inhibition protects cGAMP and ATP from hydrolysis and reduces adenosine levels in the TME, activates APCs and increases T-cell infiltration promoting anticancer immunity. RBS2418 is a potent oral ENPP1 inhibitor. Here, we report pharmacokinetic (PK) and immunomodulatory properties of RBS2418 in combination with pembrolizumab (pembro) in a checkpoint-refractory high grade adrenal cancer with an immune-desert tumor phenotype at baseline. Pembro was given at 200mg IV every 3 weeks with escalating doses of RBS2418 weekly, at 100 mg p.o. BID, followed by 200 and 400 mg p.o BID. Blood samples were collected at each dose level to determine plasma RBS2418 concentration and serum ENPP1 inhibition. Peripheral blood immune cell subpopulations were analyzed by flow cytometry and TCR/RNA sequencing. All dose levels of RBS2418 with pembro were safe, well tolerated with no DLTs. Plasma concentrations (Ctrough) of RBS2418 corresponded to > 15-fold and > 30-fold above the 90% inhibition level of ENPP1 (EC90) for the 100 and 200 mg dose, respectively. cGAMP was fully stable in serum. Peripheral blood analyses showed a 2.1-fold increase from baseline in conventional dendritic cells (cDCs) and 2.5-fold expansion of proliferating CD4/Ki67 T cells. Furthermore, CD8/Ki67 proliferating T cells increased 19.5-fold from baseline. TCR/RNA sequencing showed a > 50-fold expansion in TCR CD3β clonotypes, an increase in hyperexpanded TCR clonotypes and upregulation of granzyme B, perforin and granulysin gene expression. RBS2418 with pembro was safe, well tolerated with no DLTs. RBS2418 PK data showed excellent oral bioavailability with plasma levels leading to complete ENPP1 inhibition. RBS2418 induced increases in peripheral cDCs, proliferation of CD4 and CD8 T cells and expansion of TCR clonotypes as well as upregulation of T cell cytotoxic granule protein gene expression supporting clinical development of this novel first-in-class immunotherapy agent in an ongoing clinical trial (NCT05270213)." @default.
- W4311144477 created "2022-12-23" @default.
- W4311144477 creator A5013598326 @default.
- W4311144477 creator A5016913455 @default.
- W4311144477 creator A5034049980 @default.
- W4311144477 creator A5046897099 @default.
- W4311144477 creator A5048811075 @default.
- W4311144477 creator A5052832130 @default.
- W4311144477 creator A5071357214 @default.
- W4311144477 creator A5071829278 @default.
- W4311144477 creator A5073848393 @default.
- W4311144477 creator A5085365177 @default.
- W4311144477 creator A5088780255 @default.
- W4311144477 creator A5088883778 @default.
- W4311144477 date "2022-12-01" @default.
- W4311144477 modified "2023-09-26" @default.
- W4311144477 title "169P Immunomodulatory effects of RBS2418, an oral ENPP1 inhibitor in combination with pembrolizumab in checkpoint-refractory metastatic adrenal cancer" @default.
- W4311144477 doi "https://doi.org/10.1016/j.iotech.2022.100281" @default.
- W4311144477 hasPublicationYear "2022" @default.
- W4311144477 type Work @default.
- W4311144477 citedByCount "0" @default.
- W4311144477 crossrefType "journal-article" @default.
- W4311144477 hasAuthorship W4311144477A5013598326 @default.
- W4311144477 hasAuthorship W4311144477A5016913455 @default.
- W4311144477 hasAuthorship W4311144477A5034049980 @default.
- W4311144477 hasAuthorship W4311144477A5046897099 @default.
- W4311144477 hasAuthorship W4311144477A5048811075 @default.
- W4311144477 hasAuthorship W4311144477A5052832130 @default.
- W4311144477 hasAuthorship W4311144477A5071357214 @default.
- W4311144477 hasAuthorship W4311144477A5071829278 @default.
- W4311144477 hasAuthorship W4311144477A5073848393 @default.
- W4311144477 hasAuthorship W4311144477A5085365177 @default.
- W4311144477 hasAuthorship W4311144477A5088780255 @default.
- W4311144477 hasAuthorship W4311144477A5088883778 @default.
- W4311144477 hasBestOaLocation W43111444771 @default.
- W4311144477 hasConcept C121608353 @default.
- W4311144477 hasConcept C126322002 @default.
- W4311144477 hasConcept C153911025 @default.
- W4311144477 hasConcept C167672396 @default.
- W4311144477 hasConcept C185592680 @default.
- W4311144477 hasConcept C19317047 @default.
- W4311144477 hasConcept C203014093 @default.
- W4311144477 hasConcept C2776090121 @default.
- W4311144477 hasConcept C2777701055 @default.
- W4311144477 hasConcept C2780057760 @default.
- W4311144477 hasConcept C502942594 @default.
- W4311144477 hasConcept C553184892 @default.
- W4311144477 hasConcept C71924100 @default.
- W4311144477 hasConcept C86803240 @default.
- W4311144477 hasConcept C8891405 @default.
- W4311144477 hasConcept C98274493 @default.
- W4311144477 hasConceptScore W4311144477C121608353 @default.
- W4311144477 hasConceptScore W4311144477C126322002 @default.
- W4311144477 hasConceptScore W4311144477C153911025 @default.
- W4311144477 hasConceptScore W4311144477C167672396 @default.
- W4311144477 hasConceptScore W4311144477C185592680 @default.
- W4311144477 hasConceptScore W4311144477C19317047 @default.
- W4311144477 hasConceptScore W4311144477C203014093 @default.
- W4311144477 hasConceptScore W4311144477C2776090121 @default.
- W4311144477 hasConceptScore W4311144477C2777701055 @default.
- W4311144477 hasConceptScore W4311144477C2780057760 @default.
- W4311144477 hasConceptScore W4311144477C502942594 @default.
- W4311144477 hasConceptScore W4311144477C553184892 @default.
- W4311144477 hasConceptScore W4311144477C71924100 @default.
- W4311144477 hasConceptScore W4311144477C86803240 @default.
- W4311144477 hasConceptScore W4311144477C8891405 @default.
- W4311144477 hasConceptScore W4311144477C98274493 @default.
- W4311144477 hasLocation W43111444771 @default.
- W4311144477 hasOpenAccess W4311144477 @default.
- W4311144477 hasPrimaryLocation W43111444771 @default.
- W4311144477 hasRelatedWork W1778379190 @default.
- W4311144477 hasRelatedWork W1959193829 @default.
- W4311144477 hasRelatedWork W1976419594 @default.
- W4311144477 hasRelatedWork W2003242925 @default.
- W4311144477 hasRelatedWork W2020684972 @default.
- W4311144477 hasRelatedWork W2059422010 @default.
- W4311144477 hasRelatedWork W2128905008 @default.
- W4311144477 hasRelatedWork W2140205174 @default.
- W4311144477 hasRelatedWork W2796404166 @default.
- W4311144477 hasRelatedWork W4285984885 @default.
- W4311144477 hasVolume "16" @default.
- W4311144477 isParatext "false" @default.
- W4311144477 isRetracted "false" @default.
- W4311144477 workType "article" @default.